scholarly journals A Perioperative Smoking Cessation Intervention with Varenicline

2012 ◽  
Vol 117 (4) ◽  
pp. 755-764 ◽  
Author(s):  
Jean Wong ◽  
Amir Abrishami ◽  
Yiliang Yang ◽  
Amna Zaki ◽  
Zeev Friedman ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Relative Risk ◽  
Adverse Events ◽  
Odds Ratio ◽  
Controlled Trial ◽  
Smoking Cessation Intervention ◽  
Point Prevalence ◽  
Serious Adverse Events ◽  
Cessation Intervention ◽  
Point Prevalence Abstinence

Background The efficacy of perioperative tobacco interventions on long-term abstinence and the safety of smoking cessation less than 4 weeks before surgery is unclear. Our objective was to determine the efficacy and safety of a perioperative smoking cessation intervention with varenicline to reduce smoking in elective surgical patients. Methods In a prospective, multicenter, double-blind, placebo-controlled trial, 286 patients were randomized to receive varenicline or placebo. Both groups received in-hospital and telephone counseling during 12 months. The primary outcome was the 7-day point prevalence abstinence rate 12 months after surgery. Secondary outcomes included abstinence at 3 and 6 months after surgery. Multivariable logistic regression was used to identify independent variables related to abstinence. Results The 7-day point prevalence abstinence at 12 months for varenicline versus placebo was 36.4% versus 25.2% (relative risk: 1.45; 95%: CI: 1.01-2.07; P = 0.04). At 3 and 6 months, the 7-day point prevalence abstinence was 43.7% versus 31.9% (relative risk: 1.37; 95% CI: 1.01 to 1.86; P = 0.04), and 35.8% versus 25.9% (relative risk: 1.43; 95%: CI 1.01-2.04; P = 0.04) for varenicline versus placebo, respectively. Treatment with varenicline (odds ratio: 1.76; 95% CI: 1.03-3.01; P = 0.04), and preoperative nicotine dependence (odds ratio: 0.82, 95% CI: 0.68 to 0.98; P = 0.03) predicted abstinence at 12 months. The adverse events profile in both groups was similar except for nausea, which occurred more frequently for varenicline versus placebo (13.3% vs. 3.7%, P = 0.004). Conclusions A perioperative smoking cessation intervention with varenicline increased abstinence from smoking 3, 6, and 12 months after elective noncardiac surgery with no increase in serious adverse events.

scholarly journals Efficacy of a universal smoking cessation intervention initiated in inpatient psychiatry and continued post-discharge: A randomised controlled trial

2017 ◽  
Vol 51 (4) ◽  
pp. 366-381 ◽  
Author(s):  
Alexandra P Metse ◽  
John Wiggers ◽  
Paula Wye ◽  
Luke Wolfenden ◽  
Megan Freund ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Randomised Controlled Trial ◽  
Odds Ratio ◽  
Controlled Trial ◽  
Psychiatric Inpatient ◽  
Point Prevalence ◽  
Post Discharge ◽  
Inpatient Psychiatry ◽  
Cessation Intervention ◽  
Randomised Controlled

Objective: Interventions are required to redress the disproportionate tobacco-related health burden experienced by persons with a mental illness. This study aimed to assess the efficacy of a universal smoking cessation intervention initiated within an acute psychiatric inpatient setting and continued post-discharge in reducing smoking prevalence and increasing quitting behaviours. Method: A randomised controlled trial was undertaken across four psychiatric inpatient facilities in Australia. Participants ( N = 754) were randomised to receive either usual care ( n = 375) or an intervention comprising a brief motivational interview and self-help material while in hospital, followed by a 4-month pharmacological and psychosocial intervention ( n = 379) upon discharge. Primary outcomes assessed at 6 and 12 months post-discharge were 7-day point prevalence and 1-month prolonged smoking abstinence. A number of secondary smoking-related outcomes were also assessed. Subgroup analyses were conducted based on psychiatric diagnosis, baseline readiness to quit and nicotine dependence. Results: Seven-day point prevalence abstinence was higher for intervention participants (15.8%) than controls (9.3%) at 6 months post-discharge (odds ratio = 1.07, p = 0.04), but not at 12 months (13.4% and 10.0%, respectively; odds ratio = 1.03, p = 0.25). Significant intervention effects were not found on measures of prolonged abstinence at either 6 or 12 months post-discharge. Differential intervention effects for the primary outcomes were not detected for any subgroups. At both 6 and 12 months post-discharge, intervention group participants were significantly more likely to smoke fewer cigarettes per day, have reduced cigarette consumption by ⩾50% and to have made at least one quit attempt, relative to controls. Conclusions: Universal smoking cessation treatment initiated in inpatient psychiatry and continued post-discharge was efficacious in increasing 7-day point prevalence smoking cessation rates and related quitting behaviours at 6 months post-discharge, with sustained effects on quitting behaviour at 12 months. Further research is required to identify strategies for achieving longer term smoking cessation.

scholarly journals Decídetexto: Feasibility and Acceptability of a Mobile Smoking Cessation Intervention in Puerto Rico

2021 ◽  
Vol 18 (4) ◽  
pp. 1379
Author(s):  
Francisco Cartujano-Barrera ◽  
Cristina Peña-Vargas ◽  
Evelyn Arana-Chicas ◽  
José Pérez-Ramos ◽  
Josiemer Mattei ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Puerto Rico ◽  
Pilot Study ◽  
Self Efficacy ◽  
Text Messaging ◽  
Smoking Cessation Intervention ◽  
Point Prevalence ◽  
Cessation Intervention ◽  
Point Prevalence Abstinence

The purpose of this pilot study was to assess the feasibility and acceptability of a mobile smoking cessation intervention in Puerto Rico. This was a single-arm pilot study with 26 smokers in Puerto Rico who were enrolled in Decídetexto, a mobile smoking cessation intervention. Decídetexto incorporates three integrated components: (1) a tablet-based software that collects smoking-related information to develop an individualized quit plan, (2) a 24-week text messaging counseling program with interactive capabilities, and (3) pharmacotherapy support. Outcome measures included self-reported 7-day point prevalence abstinence at Months 3 and 6, pharmacotherapy adherence, satisfaction with the intervention, and changes in self-efficacy. The average age of the participants was 46.8 years (SD 12.7), half of them (53.8%) were female. Most participants (92.3%) smoked daily and half of them (53.8%) used menthol cigarettes. All participants requested nicotine patches at baseline. However, only 13.0% of participants used the patch >75% of days. At Month 3, 10 participants (38.4%) self-reported 7-day point prevalence abstinence (88.5% follow-up rate). At Month 6, 16 participants (61.5%) self-reported 7-day point prevalence abstinence (76.9% follow-up rate). Most participants (90%, 18/20) reported being satisfied/extremely satisfied with the intervention at Month 6. Self-efficacy mean scores significantly increased from 40.4 (SD 12.1) at baseline to 57.9 (SD 11.3) at Month 3 (p < 0.01). The study suggests that Decídetexto holds promise for further testing among Puerto Rican smokers.

scholarly journals A Randomized Controlled Trial of a Tailored Group Smoking Cessation Intervention for HIV-Infected Smokers

2012 ◽  
Vol 61 (2) ◽  
pp. 208-215 ◽  
Author(s):  
Alyson B. Moadel ◽  
Steven L. Bernstein ◽  
Robin J. Mermelstein ◽  
Julia H. Arnsten ◽  
Eileen H. Dolce ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Smoking Cessation ◽  
Controlled Trial ◽  
Smoking Cessation Intervention ◽  
Randomized Controlled ◽  
Cessation Intervention

Randomized controlled trial of a midwife-delivered brief smoking cessation intervention in pregnancy

Addiction ◽  
2001 ◽  
Vol 96 (3) ◽  
pp. 485-494 ◽  
Author(s):  
Peter Hajek ◽  
Robert West ◽  
Anne Lee ◽  
Jonathan Foulds ◽  
Lesley Owen ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Smoking Cessation ◽  
Controlled Trial ◽  
Smoking Cessation Intervention ◽  
Randomized Controlled ◽  
Cessation Intervention ◽  
In Pregnancy

The Impact of a Brief Intervention on Maternal Smoking Behavior

PEDIATRICS ◽  
2000 ◽  
Vol 105 (Supplement_2) ◽  
pp. 267-271
Author(s):  
Judith A. Groner ◽  
Karen Ahijevych ◽  
Lindsey K. Grossman ◽  
Leslie N. Rich
Keyword(s):  
Smoking Cessation ◽  
Controlled Trial ◽  
Safety Information ◽  
Stage Of Change ◽  
Smoking Cessation Intervention ◽  
Control Group ◽  
Primary Care Center ◽  
Cessation Intervention ◽  
Quit Rate ◽  
The Impact

Objective. To determine if mothers receiving a smoking cessation intervention emphasizing health risks of environmental tobacco smoke (ETS) for their children have a higher quit rate than 1) mothers receiving routine smoking cessation advice or 2) a control group. Design. Randomized, controlled trial. Setting. Primary care center in a large urban children's hospital. Intervention. Four hundred seventy-nine mothers were randomly assigned to a smoking cessation intervention either aimed at their child's health or their own health, or to a control group receiving safety information. Outcome Measures. Smoking status, stage of change, cigarettes/day, location smoking occurred, and knowledge of ETS effects. Results. Complete data (baseline and both follow-ups) were available for 166 subjects. There was no impact of group assignment on the quit rate, cigarettes/day, or stage of change. The Child Health Group intervention had a sustained effect on location where smoking reportedly occurred (usually outside) and on improved knowledge of ETS effects. Conclusions. Further research is needed to devise more effective methods of using the pediatric health care setting to influence adult smoking behaviors.

Sign in / Sign up

Export Citation Format

Share Document